The US Food & Drug Administration (FDA) has extended the shelf life for US pharmaceutical company Johnson & Johnson's (NYSE:JNJ) single-shot COVID-19 vaccine to six months from four-and-a-half months, Reuters news agency reported on Thursday.
According to J&J, the FDA's decision is based on data from ongoing studies which show the vaccine is stable at six months when refrigerated at two to eight degrees Celsius.
The FDA stated in a letter to J&J that the extension was also applicable to batches that might have expired prior to the issuance of the letter, provided they were stored at the recommended temperature.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates